

Obefazimod data to be presented:

Presentation Title	Session	Presenter	Presentation/ Session Number	Session Hall	Date and Time (EDT)
Oral Presentation					
"Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QD"	Digital Oral Presentation Session 6	Prof. Silvio Danese, MD, PhD Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital	Clinical Trials III	Hall A7	Friday, February 21, 2025 8:42am to 8:48pm
Poster Presentations					
"Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study"	Guided Poster Session	Fernando Magro, MD, PhD President-Elect of ECCO. Head of the Department of Clinical Pharmacology and Professor of Pharmacology and Therapeutics at University Hospital São João in Porto, Portugal	Poster number: P0636	Hall 2.2	Friday, February 21, 2025 12:40pm to 1:40pm
"Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis"	Guided Poster Session	Prof. Séverine Vermeire, MD, PhD Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study programs conducted and ongoing with obefazimod in UC	Poster number: P0813	Hall 2.2	Friday, February 21, 2025 12:40pm to 1:40pm
"Health-related quality of life (HRQOL) in patients with ulcerative colitis (UC) treated with obefazimod: the phase 2	Guided Poster Session	Jennifer Fine, ScD Head of HEOR, Abivax S. A	Poster number: P0840	Hall 2.2	Friday, February 21, 2025

open-label maintenance study"					12:40pm to 1:40pm
"Efficacy and safety of obefazimod for the fourth and sixth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): 2-year interim analysis after dose de-escalation to 25 mg"	Guided Poster Session	Prof. Silvio Danese, MD, PhD Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital		Hall 2.2	Friday, February 21, 2025 12:40pm to 1:40pm
"Long-term treatment patterns, dose escalation, and steroid use among patients with moderate-to-severe ulcerative colitis using advanced therapies: 3 years of continuous follow-up using IQVIA PharMetrics Plus database"	Guided Poster Session	Prof. Parambir S. Dulai, M.D. Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois		Hall 2.2	Friday, February 21, 2025 12:40pm to 1:40pm
"Synergistic reduction of inflammatory cytokines with obefazimod and etrasimod in combination treatment vs. either monotherapy in a mouse model of inflammatory bowel disease"	Guided Poster Session	Didier Scherrer, PhD Chief Scientific Officer Abivax S.A.		Hall 2.2	Friday, February 21, 2025 12:40pm to 1:40pm